• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $1M Bet On This Basic Materials Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

    5/15/23 7:41:00 AM ET
    $INKT
    $PFMT
    $PZG
    $SWIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Consumer Discretionary
    Get the next $INKT alert in real time by email

    The Dow Jones closed slightly lower on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Paramount Gold Nevada

    • The Trade: Paramount Gold Nevada Corp. (NYSE:PZG) 10% owner Albert Friedberg acquired a total 4,300,000 shares an average price of $0.32. To acquire these shares, it cost around $1.38 million.
    • What’s Happening: The company’s stock dropped 17% over the past month.
    • What Paramount Gold Nevada Does: Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, it is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States.

    MiNK Therapeutics

    • The Trade: MiNK Therapeutics, Inc. (NASDAQ:INKT) 10% owner Agenus Inc acquired a total of 45,426 shares at an average price of $1.47. The insider spent around $66.64 thousand to buy those shares.
    • What’s Happening: MiNK Therapeutics reported a narrower-than-expected Q1 loss.
    • What MiNK Therapeutics Does: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

    Performant Financial

    • The Trade: Performant Financial Corporation (NASDAQ:PFMT) 10% owner Phil Frohlich acquired a total of 30,000 shares at an average price of $2.61. To acquire these shares, it cost around $78.3 thousand.
    • What’s Happening: Performant Finl posted a narrower-than-expected quarterly loss.
    • What Performant Financial Does: Performant Financial Corp provides technology-enabled recovery and related analytics services in the United States.

    Latham Group

    • The Trade: Latham Group, Inc. (NASDAQ:SWIM) Director James Cline acquired a total of 50,000 shares at an average price of $3.40. The insider spent $170 thousand to buy those shares.
    • What’s Happening: Latham Group reported better-than-expected Q1 sales results.
    • What Latham Group Does: Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand.

     

    Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Materials Stocks Delivering High-Dividend Yields

    Don’t forget to check out our premarket coverage here

    Get the next $INKT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INKT
    $PFMT
    $PZG
    $SWIM

    CompanyDatePrice TargetRatingAnalyst
    MiNK Therapeutics Inc.
    $INKT
    8/15/2025$35.00Neutral → Buy
    H.C. Wainwright
    MiNK Therapeutics Inc.
    $INKT
    7/14/2025Outperform → Mkt Perform
    William Blair
    Latham Group Inc.
    $SWIM
    12/9/2024$10.00Buy
    Craig Hallum
    Performant Healthcare Inc.
    $PFMT
    7/25/2024$8.00Buy
    B. Riley Securities
    Latham Group Inc.
    $SWIM
    3/18/2024$3.00 → $4.00Hold → Buy
    Stifel
    Latham Group Inc.
    $SWIM
    3/13/2024$4.50 → $2.60Buy → Underperform
    BofA Securities
    Performant Healthcare Inc.
    $PFMT
    12/20/2022$8.00Buy
    Lake Street
    Latham Group Inc.
    $SWIM
    12/14/2022$7.00 → $5.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $INKT
    $PFMT
    $PZG
    $SWIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

    Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ:INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1–4, 2026, in Banff, Alberta, Canada. The data, presented by Dr. Terese Hammond, Head

    2/3/26 9:30:00 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Latham Group, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Date

    LATHAM, N.Y., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Latham Group, Inc. (NASDAQ:SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, March 3, 2026, after the close of the U.S. market. The Company will hold a conference call to discuss the results that same day at 4:30 PM Eastern Time. We encourage participants to pre-register for the conference call by visiting https://dpregister.com/sreg/10205712/1030db875c0. Callers who pre-register will be sent a confirmation e-mail including a conference passcod

    2/3/26 4:30:00 PM ET
    $SWIM
    Plastic Products
    Industrials

    Paramount Gold Receives Federal Approval for the Grassy Mountain Gold Project

    WINNEMUCCA, Nev., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE:PZG) ("Paramount" or the "Company") announced today that the Record of Decision ("ROD") for its Grassy Mountain Gold Project ("Grassy Mountain"), located in Malheur County, Oregon has been signed. The issuance of the ROD represents the culmination of the federal environmental review process under the National Environmental Policy Act ("NEPA"). The Final Environmental Impact Statement (FEIS) incorporates feedback received during the public comment period and reflects the BLM's rigorous environmental, socio-economic and alternative analysis to support responsible development on federal lands for the benefi

    1/29/26 4:47:01 PM ET
    $PZG
    Metal Mining
    Basic Materials

    $INKT
    $PFMT
    $PZG
    $SWIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Espley Samantha Jane converted options into 20,000 shares, increasing direct ownership by 15% to 150,000 units (SEC Form 4)

    4 - Paramount Gold Nevada Corp. (0001629210) (Issuer)

    1/29/26 6:05:03 PM ET
    $PZG
    Metal Mining
    Basic Materials

    SEC Form 4 filed by Director Espley Samantha Jane

    4 - Paramount Gold Nevada Corp. (0001629210) (Issuer)

    1/29/26 6:00:03 PM ET
    $PZG
    Metal Mining
    Basic Materials

    Chief Executive Officer Goldman Rachel Louise converted options into 88,750 shares, increasing direct ownership by 11% to 895,672 units (SEC Form 4)

    4 - Paramount Gold Nevada Corp. (0001629210) (Issuer)

    1/28/26 6:57:28 PM ET
    $PZG
    Metal Mining
    Basic Materials

    $INKT
    $PFMT
    $PZG
    $SWIM
    SEC Filings

    View All

    SEC Form 10-Q filed by Paramount Gold Nevada Corp.

    10-Q - Paramount Gold Nevada Corp. (0001629210) (Filer)

    2/10/26 4:30:46 PM ET
    $PZG
    Metal Mining
    Basic Materials

    SEC Form SCHEDULE 13G filed by Latham Group Inc.

    SCHEDULE 13G - Latham Group, Inc. (0001833197) (Subject)

    2/10/26 11:21:52 AM ET
    $SWIM
    Plastic Products
    Industrials

    MiNK Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

    1/2/26 4:05:22 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    $PFMT
    $PZG
    $SWIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MiNK Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded MiNK Therapeutics from Neutral to Buy and set a new price target of $35.00

    8/15/25 8:13:07 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics downgraded by William Blair

    William Blair downgraded MiNK Therapeutics from Outperform to Mkt Perform

    7/14/25 8:40:54 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Latham Group with a new price target

    Craig Hallum initiated coverage of Latham Group with a rating of Buy and set a new price target of $10.00

    12/9/24 8:42:41 AM ET
    $SWIM
    Plastic Products
    Industrials

    $INKT
    $PFMT
    $PZG
    $SWIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dellaquila Frank J bought $41,200 worth of shares (5,000 units at $8.24), increasing direct ownership by 30% to 21,814 units (SEC Form 4)

    4 - Latham Group, Inc. (0001833197) (Issuer)

    8/25/25 11:42:02 AM ET
    $SWIM
    Plastic Products
    Industrials

    Large owner Fcmi Parent Co. bought $249,600 worth of shares (416,000 units at $0.60) (SEC Form 4)

    4 - Paramount Gold Nevada Corp. (0001629210) (Issuer)

    6/18/25 4:30:48 PM ET
    $PZG
    Metal Mining
    Basic Materials

    CHIEF FINANCIAL OFFICER Gloe Oliver C. bought $82,350 worth of shares (13,500 units at $6.10), increasing direct ownership by 3% to 466,630 units (SEC Form 4)

    4 - Latham Group, Inc. (0001833197) (Issuer)

    5/16/25 4:14:43 PM ET
    $SWIM
    Plastic Products
    Industrials

    $INKT
    $PFMT
    $PZG
    $SWIM
    Financials

    Live finance-specific insights

    View All

    Latham Group, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Date

    LATHAM, N.Y., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Latham Group, Inc. (NASDAQ:SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, March 3, 2026, after the close of the U.S. market. The Company will hold a conference call to discuss the results that same day at 4:30 PM Eastern Time. We encourage participants to pre-register for the conference call by visiting https://dpregister.com/sreg/10205712/1030db875c0. Callers who pre-register will be sent a confirmation e-mail including a conference passcod

    2/3/26 4:30:00 PM ET
    $SWIM
    Plastic Products
    Industrials

    MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

    New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Phase 2+ trial in severe pulmonary disease in US population with FDA-validated endpointsAdded national leaders in pulmonary medicine, trauma, and biodefense join MiNK management (Dr. Hammond) and Board (Dr. Holcomb) to drive pivotal developmentCash runway extended through 2026, enabling multiple inflection points NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneeri

    11/14/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK's late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company's agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives

    11/5/25 9:07:20 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    $PFMT
    $PZG
    $SWIM
    Leadership Updates

    Live Leadership Updates

    View All

    Latham Group Appoints Sean Gadd as Chief Executive Officer

    Latham's Board of Directors has appointed Sean Gadd as President and CEO following a comprehensive succession planning processMr. Gadd joins following a 21-year career at James Hardie, where he most recently served as President of North AmericaScott Rajeski has decided to retire after more than 8 years as CEO and will serve as a special advisor to the company LATHAM, N.Y., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Latham Group, Inc. (NASDAQ:SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, appoints Sean Gadd as the company's new President and Chief Executive Officer as part of a CEO transition that will ta

    12/8/25 4:15:00 PM ET
    $SWIM
    Plastic Products
    Industrials

    MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocol

    9/29/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

    Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationally recognized leader in pulmonary and critical care medicine with extensive experience advancing registration-stage programs in severe pulmonary and inflammatory diseases. She has served as principal inves

    9/18/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INKT
    $PFMT
    $PZG
    $SWIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Performant Financial Corporation

    SC 13G/A - Performant Financial Corp (0001550695) (Subject)

    11/15/24 7:03:26 AM ET
    $PFMT
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Performant Financial Corporation

    SC 13G/A - Performant Financial Corp (0001550695) (Subject)

    11/14/24 4:41:31 PM ET
    $PFMT
    Other Consumer Services
    Consumer Discretionary

    SEC Form SC 13G filed by MiNK Therapeutics Inc.

    SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

    5/22/24 4:33:15 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care